The best today for a better tomorrow: a standard of practice to both recognise and develop infectious diseases pharmacy

Abstract

Infectious disease is a multidisciplinary specialty involving infectious diseases physicians, clinical microbiologists, nurses and pharmacists among other specialities. Given that so much of infectious diseases involves antimicrobial drugs, it is obvious that pharmacists are an integral part of the care of patients with infections. Infectious diseases pharmacy has developed as its own specialty over the last 10–15 years with the development of antimicrobial stewardship programs, which are now a requirement of hospital accreditation. For those of us that have the privilege of working with specialist ID pharmacists, there are few days that we would not call upon their expertise for difficult areas – HIV drug interactions, dosing in organ failure and critically ill patients, the more unusual antibiotic interactions, and hospital in the home programs, for example. Australian pharmacists have also contributed immensely to areas outside of direct clinical care. In research, The Australian newspaper named Prof Jason Roberts as the leading national researcher in the fields of both critical care and communicable diseases in 2019.1 Many other examples of the impact of pharmacists are provided in this document. Pharmacists have led the ongoing development of Australian national treatment guidelines, Therapeutic Guidelines, while providing key insights into quality and safety programs at state and national levels, as well as contributing to the National COVID-19 Evidence Task Force, among many other contributions. The SHPA Standard of Practice in Infectious Diseases for Pharmacy Services, published in this issue, crystallises the skills and scope that pharmacists have in the management of infectious diseases, particularly in providing clinical care but also into broader governance systems. These include ensuring the quality use of antimicrobials (through education, antimicrobial stewardship programs, developing and reviewing policies and procedures) and ensuring access through formulary policies. The immediate impact of the Standard is to form the basis for a curriculum for junior pharmacists intending to specialise in this area, or for general pharmacists who may require skills in this area in other settings, such as rural hospitals or community settings. Advanced training for physicians has evolved from an “apprenticeship” model to a more structured educational model. While most currently available post-graduate courses are international, a standardised curriculum should facilitate local training and education initiatives, analogous to accreditation developed for infection prevention and control nurses by the Australasian College of Infection Prevention and Control. Collaborative guidance such as this Standard will help future ID pharmacists to build on existing roles and extend into emerging areas of practice. It should be noted that like the scope of practice of pharmacists more generally, this will continue to evolve and expand over time. The infectious diseases community welcomes this major step in recognising the expertise of infectious diseases pharmacists and their contribution to clinical care and the systems that support healthcare. The author has no conflicts of interest to declare.